WeightWatchers' CEO said it plans to offer Novo Nordisk's much-anticipated Wegovy in pill form if it is launched next year in the United States.
In this article
WeightWatchers’
CEO said on Wednesday it plans to offer Novo Nordisk’s
much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker.
The collaboration is a potential boost for WeightWatchers as it emerges from bankruptcy and highlights its commitment to offer branded obesity drugs, unlike rivals that push cheaper copies in a highly competitive market.
The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.
Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via WeightWatchers Med+ from $149 per month for…
Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via WeightWatchers Med+ from $149 per month for…
It marks a first in this new era of weight-loss medications with Wegovy being the only so far to gain approval for a pill version…
Food and Drug Administration’s approval hands drugmaker Novo Nordisk an edge in the race to market an obesity pill
The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.
